Isomorphic Labs, a London-based biotechnology innovator, announced a $600 million funding round led by Thrive Capital. The company leverages AI to advance drug design and development and plans to invest the money in furthering its drug candidate pipeline.
Operating an AI-powered drug design engine, Isomorphic Labs aims to advance drug design programs across various therapeutic areas and drug modalities. The company’s models include AlphaFold 3, developed in partnership with Google DeepMind, which works to accurately predict the structure and interactions of all biological molecules. Its portfolio also consists of internal oncology and immunology programs, alongside pharmaceutical partner programs.
Backed by its new capital, Isomorphic Labs will focus on AI research and development to advance its drug design engine. As the company works toward establishing new patient treatments, it has plans to expand its team while fueling its next stage of growth.
